Literature DB >> 8680545

Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide.

C Hirayama1, H Suzuki, A Takada, K Fujisawa, K Tanikawa, S Igarashi.   

Abstract

The clinical significance of the immunoreactive triple helical domain of type IV collagen in serum was evaluated in 73 healthy controls and 161 patients with various biopsy-proven liver diseases. Although serum levels of type III procollagen peptide were increased in all liver diseases, those of type IV collagen, 7S collagen, and laminin were principally increased in chronic liver diseases associated with hepatic fibrogenesis/fibrosis. In both non-alcoholic and alcoholic liver diseases, 7S collagen was increased in serum, while type IV collagen and laminin in serum were particularly increased in alcoholic liver diseases and in hepatocellular carcinoma, in which latter the sensitivity was greater for type IV collagen than for laminin. Gel filtration analysis in Sephacryl S-400 revealed type IV collagen in serum to be a single molecular form with a molecular weight that correspond to type IV collagen, whereas 7S collagen was recognized as several heterogeneous macromolecules. These findings indicate that serum type IV collagen is derived from the type IV protocollagen pool, and is a sensitive marker for the fibrogenetic process in hepatic basement membranes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680545     DOI: 10.1007/bf02389524

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

1.  Heterogeneity of antigens related to 7S domain of type IV collagen in serum: application to patients with chronic liver disease.

Authors:  S Yamada; Y Kishimoto; T Suou; H Kawasaki; Y Horie
Journal:  Clin Chim Acta       Date:  1992-11-16       Impact factor: 3.786

2.  Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis.

Authors:  K D Bentsen; J H Henriksen; F Bendtsen; K Hørslev-Petersen; I Lorenzen
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

3.  Radioimmunoassay of type I collagen that mainly detects degradation products in serum: application to patients with liver diseases.

Authors:  D J Hartmann; J C Trinchet; S Ricard-Blum; M Beaugrand; P Callard; G Ville
Journal:  Clin Chem       Date:  1990-03       Impact factor: 8.327

4.  Hepatocytes may produce laminin in fibrotic liver and in primary culture.

Authors:  B Clément; P Y Rescan; G Baffet; O Loréal; D Lehry; J P Campion; A Guillouzo
Journal:  Hepatology       Date:  1988 Jul-Aug       Impact factor: 17.425

5.  Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin).

Authors:  P A Bejarano; M E Noelken; K Suzuki; B G Hudson; H Nagase
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

6.  Increased amount of serum type IV collagen peptide in human liver fibrosis as determined by enzyme-immunoassay with monoclonal antibodies.

Authors:  E Matsumoto; Y Muragaki; A Ooshima
Journal:  Acta Pathol Jpn       Date:  1989-04

7.  Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin.

Authors:  E Hahn; G Wick; D Pencev; R Timpl
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

8.  Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases.

Authors:  J Kropf; A M Gressner; A Negwer
Journal:  Clin Chem       Date:  1988-10       Impact factor: 8.327

9.  Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse. Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan.

Authors:  K D Bentsen; T Horn; J Risteli; L Risteli; A Engström-Laurent; K Hørslev-Petersen; I Lorenzen
Journal:  Liver       Date:  1987-12

10.  Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease.

Authors:  A Hayasaka; D Schuppan; K Ohnishi; K Okuda; E G Hahn
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

View more
  7 in total

1.  Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients.

Authors:  Man Wang; Rongrong Liu; Yuzhen Liang; Gaohui Yang; Yumei Huang; Chunlan Yu; Kaiqi Sun; Yongrong Lai; Yang Xia
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 2.  The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Food Chem Toxicol       Date:  2020-07-05       Impact factor: 6.023

3.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

4.  Biomarker profile in stable Fontan patients.

Authors:  Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book
Journal:  Int J Cardiol       Date:  2020-01-09       Impact factor: 4.164

5.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

Review 6.  Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment.

Authors:  Claire E McQuitty; Roger Williams; Shilpa Chokshi; Luca Urbani
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

7.  The association of laminin levels with insulin resistance and non-alcoholic hepatosteatosis.

Authors:  Özgür Altun; Yücel Arman; Şengül Aydın Yoldemir; Ayşe Selcen Pala; Perihan Özkan Gümüşkaya; Mustafa Özcan; Mustafa Karataş; Okan Dikker; Tufan Tükek
Journal:  Diabetol Metab Syndr       Date:  2021-06-06       Impact factor: 3.320

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.